Lyell Immunopharma Inc (LYEL) Stock Price, Quote & News

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment...

Industry: Biotechnology

Sector: Healthcare

Phone: (650) 695-0677

Website: www.lyell.com

Address:

201 Haskins Way, South San Francisco, United States

fantastex Aug. 20 at 1:21 PM

$LYEL promising pipeline at only 200m market cap with 290m cash + 50m from private placement? Low cash burn around 42m per quarter. Whoever sees good results here will takeover the company 100% for 5/6x current price (55 dollars minimum). Undervalued af.

0 · Reply

KeyImpatience Aug. 18 at 5:26 PM

$LYEL From the looks of it - stock is not liquid enough to make any large purchases without shooting up the SP. big boys/friends/family wanted in at this discount so they went with a private placement. They didn’t need money, especially raising at this low price… odd

1 · Reply

fantastex Aug. 16 at 8:45 AM

$LYEL this big time. Lets see a 2025 plenty of big Surprises

0 · Reply

valueforme Aug. 14 at 1:56 AM

$LYEL I tried to buy something sizable, but no liquidity at all in this name...

4 · Reply

fantastex Aug. 13 at 8:58 PM

$LYEL halted for volatility but still low volume. What the hell is going here ?

0 · Reply

Allergictobears Aug. 13 at 1:54 PM

What is this halt??? $LYEL

1 · Reply

HaltTradeAlert Aug. 13 at 1:51 PM

$LYEL Halt Time: 09:49:22 Issue Symbol: LYEL Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

0 · Reply

Polip Aug. 13 at 9:51 AM

$LYEL Reported 17 usd per share in cash and direct offering. Bill Gates bought 5% recently. $XBI

0 · Reply

d_risk Aug. 13 at 6:15 AM

$LYEL - Lyell Immunopharma Inc. Common Stock - 10Q - Updated Risk Factors LYEL’s 10-Q risk factors now stress late-stage cell therapy focus, major integration and expense risks from ImmPACT, expanded clinical, regulatory, and IP litigation hurdles, new cybersecurity and compliance threats, and highlight stock volatility, dilution, and public company cost pressures. #CellTherapy #Cybersecurity #IPLitigation #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/LYEL/10-Q/2025-08-12

0 · Reply

fantastex Aug. 12 at 9:53 PM

$LYEL $BMY is targeting this Company for a buyout offer in mid-2026 imho for roughly 1.2B (70$). lets Hope!

0 · Reply

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Jul 25, 2025, 8:00 AM EDT - 4 weeks ago

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Jul 22, 2025, 9:02 AM EDT - 4 weeks ago

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Jun 23, 2025, 5:00 PM EDT - 2 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 17, 2025, 6:30 AM EDT - 2 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 9, 2025, 4:05 PM EDT - 2 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 4, 2025, 4:05 PM EDT - 2 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

May 13, 2025, 4:05 PM EDT - 3 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 1, 2025, 9:00 AM EDT - 4 months ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

$Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma$

Apr 15, 2025, 9:00 AM EDT - 4 months ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Mar 11, 2025, 4:05 PM EDT - 5 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 6 months ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Jan 9, 2025, 9:00 AM EST - 8 months ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Dec 9, 2024, 9:00 PM EST - 9 months ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Nov 5, 2024, 9:30 AM EST - 10 months ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Oct 31, 2024, 4:00 PM EDT - 10 months ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 25, 2024, 9:24 AM EDT - 10 months ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 24, 2024, 4:00 PM EDT - 10 months ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 4, 2024, 9:00 AM EDT - 11 months ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 24, 2024, 4:05 PM EDT - 11 months ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

May 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Apr 16, 2024, 6:25 PM EDT - 1 year ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Mar 5, 2024, 4:30 PM EST - 1 year ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Feb 28, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 26, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Jan 3, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Nov 10, 2023, 2:23 PM EST - 1 year ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 9, 2023, 4:05 PM EST - 1 year ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 7, 2023, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 26, 2023, 9:29 AM EDT - 2 years ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

May 4, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 2, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Feb 28, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Jan 3, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Dec 15, 2022, 7:00 AM EST - 2 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Dec 1, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Nov 10, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Nov 8, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

Nov 7, 2022, 8:05 AM EST - 3 years ago

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Oct 6, 2022, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Oct 5, 2022, 8:05 AM EDT - 3 years ago

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

fantastex Aug. 20 at 1:21 PM

0 · Reply

KeyImpatience Aug. 18 at 5:26 PM

1 · Reply

fantastex Aug. 16 at 8:45 AM

$LYEL this big time. Lets see a 2025 plenty of big Surprises

0 · Reply

valueforme Aug. 14 at 1:56 AM

$LYEL I tried to buy something sizable, but no liquidity at all in this name...

4 · Reply

fantastex Aug. 13 at 8:58 PM

$LYEL halted for volatility but still low volume. What the hell is going here ?

0 · Reply

Allergictobears Aug. 13 at 1:54 PM

What is this halt??? $LYEL

1 · Reply

HaltTradeAlert Aug. 13 at 1:51 PM

0 · Reply

Polip Aug. 13 at 9:51 AM

$LYEL Reported 17 usd per share in cash and direct offering. Bill Gates bought 5% recently. $XBI

0 · Reply

d_risk Aug. 13 at 6:15 AM

0 · Reply

fantastex Aug. 12 at 9:53 PM

$LYEL $BMY is targeting this Company for a buyout offer in mid-2026 imho for roughly 1.2B (70$). lets Hope!

0 · Reply

fantastex Aug. 12 at 9:51 PM

$LYEL many sleepers on this. Only ~45M of cash burn per quarter, and they still have 297M of cash in the bank end of Q2 2025. Any positive news and this gets to 700-800M market cap overnight. Aiming to having good news by end of year.

0 · Reply

fantastex Aug. 12 at 6:34 AM

$LYEL this should be adjusted x3 like $NKTR soon. Expecting 25-30 by year end.

0 · Reply

Hopipaytrader Aug. 11 at 2:01 AM

$LYEL could that be a cup and hamburger in the 3 month

0 · Reply

KeyImpatience Aug. 6 at 11:41 PM

$LYEL Short term PT = $9 Nothing new for a few months, will check back then

0 · Reply

KeyImpatience Aug. 6 at 8:40 PM

$LYEL Good product pipeline/data, great cash position, but no news expected for next 6 months or so… likely to bleed out until next data readout?

0 · Reply

LowFloatFinders Aug. 6 at 8:03 PM

$LYEL and $TG from ChatGPT today

0 · Reply

fantastex Aug. 5 at 10:38 AM

$LYEL bill gates is usually a pumper right? I hope this company can get over 80-90$ with him. Make me a favour Bill!

0 · Reply

Polip Aug. 4 at 9:16 PM

$LYEL Bill gates just entered with 5% stake of the company. This is a hidden gem about to fly. I see the little pieces coming together. $XBI https://fintel.io/so/us/lyel

1 · Reply

Dcainedwr Aug. 4 at 7:19 PM

$LYEL Do you guys notice Bill Gates 13-G?

0 · Reply

Peterson28 Aug. 1 at 5:19 PM

$LYEL 80k traded. Very normal

1 · Reply

Peterson28 Jul. 31 at 3:20 PM

$LYEL Moving my profits from Repl to buy more shares here. Yea yea yea.

0 · Reply

fantastex Jul. 30 at 8:21 PM

$LYEL so undervalued. If $REPL is now at 500m market cap how this is at only 200 when it has multiple catalysts and 3ph trials ? Lol insane

0 · Reply

Market Cap	204.60M
Revenue (ttm)	60,000.00
Net Income (ttm)	-342.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-571,650.00%
Debt to Equity Ratio	0.00

Volume	21,700
Avg Vol	93,792
Day's Range	N/A - N/A
Shares Out	19.21M
Stochastic %K	74%
Beta	-0.19
Analysts	Hold
Price Target	$11.00